Key result
Biglycan deficiency promotes myofibroblast differentiation and proliferation in vitro and in vivo, likely due to increased responses to TGF-β and SMAD2 signaling.
Why the study?
Does biglycan deficiency promote myofibroblast differentiation and proliferation in cardiac fibroblasts?
Population
Cardiac fibroblasts isolated from hearts of wild-type versus bgn mice, and in vivo post-myocardial…
Comparison
Biglycan deficiency (bgn), reconstitution of… vs Wild-type (WT) mice and fibroblasts
Design
Preclinical
Authors
Loading...
May inform post-MI fibrosis research; leaves open translation to human cardiac remodeling.
Does biglycan deficiency promote myofibroblast differentiation and proliferation in cardiac fibroblasts?
Biglycan deficiency promotes cardiac fibroblast differentiation into myofibroblasts and proliferation via enhanced TGF-β and SMAD2 signaling, highlighting its role in post-infarct extracellular matrix remodeling.
Melchior‐Becker et al. (2011) studied Myocardial infarction and cardiac fibrosis. Biglycan deficiency (bgn(-/0)) vs. Wild-type (WT) was evaluated on Myofibroblast differentiation and proliferation. Biglycan deficiency promotes myofibroblast differentiation and proliferation in vitro and in vivo, likely due to increased responses to TGF-β and SMAD2 signaling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: